Fibroblast growth factor 2: From laboratory evidence to clinical application

Current Vascular Pharmacology

Volumn 2, Issue 1, 2004, Pages 33-43

  Chen, Chu Huang ^a   Poucher, Simon M ^b   Lu, Jonathan ^a   Henry, Philip D ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Angiogenesis; Apoptosis; Endothelial cells; FGF2; Gene therapy; Hypercholesterolemia; Phospholipids; Signal transduction

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADENOVIRUS VECTOR; ANGIOPOIETIN 2; BAG 1 PROTEIN; CADHERIN; CASPASE 3; CISPLATIN; CLENBUTEROL; EPHRIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; FLUDARABINE; ISOPRENALINE; ISOPROTEIN; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PHOSPHOLIPASE A; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROPRANOLOL; PROTEIN BCL 2; RAS PROTEIN; RECOMBINANT FIBROBLAST GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN;

ANGINA PECTORIS; ANGIOGENESIS; APOPTOSIS; AUTOCRINE EFFECT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TYPE; CLINICAL LABORATORY; CLINICAL TRIAL; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ENDOTHELIUM CELL; ENZYME INHIBITION; GENE CONTROL; GENE THERAPY; GENETIC TRANSCRIPTION; HUMAN; HYPERCHOLESTEROLEMIA; INTRACORONARY INFUSION; MESODERM; MOLECULAR MECHANICS; MOLECULAR WEIGHT; NEUROECTODERM; NONHUMAN; PARACRINE SIGNALING; PERICYTE; PROTEIN FUNCTION; RECEPTOR AFFINITY; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; START CODON; TISSUE CULTURE; VIRAL GENE DELIVERY SYSTEM;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; APOPTOSIS; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION; HUMANS; HYPERCHOLESTEROLEMIA; NEOPLASMS; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION;

EID: 2642513899     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570161043476500     Document Type: Review

References (100)

1. Gospodarowicz D. Localisation of a fibroblast growth factor and its effect alone and with hydrocortisone on 3T3 cell growth. Nature 1974; 249: 123-7.
2. Gospodarowicz D, Jones KL, Sato G. Purification of a growth factor for ovarian cells from bovine pituitary glands. Proc Natl Acad Sci USA 1974; 71: 2295-9.
3. Gospodarowicz D. Purification of a fibroblast growth factor from bovine pituitary. J Biol Chem 1975; 250: 2515-2520.
4. Gospodarowicz D, Moran J, Braun D, Birdwell CR. Clonal growth of bovine vascular endothelial cells: fibroblast growth factor as a survival agent. Proc Natl Acda Sci USA 1976; 73: 4120-4.
5. Maciag T, Cerundolo J, Ilsley S, Kelley PR, Forand R. An endothelial cell growth factor from bovine hypothalamus: identification and partial characterization. Proc Natl Acad Sci USA 1979; 76: 5674-8.
6. Thomas KA, Riley MC, Lemmon SK, Baglan NC, Bradshaw RA. Brain fibroblast growth factor: nonidentity with myelin basic protein fragments. J Biol Chem 1980; 255: 5517-20.
7. Lemmon SK, Riley MC, Thomas KA, Hoover GA, Maciag T, Bradshaw RA. Bovine fibroblast growth factor: comparison of brain and pituitary preparations. J Cell Biol 1982; 95: 162-9.
8. The fibroblast growth factor family. Nomenclature meeting report and recommendations. January 17, 1991. (Chairpersons: Baird A and Klagsbrun M) Ann N Y Acad Sci 1991; 638: xiii-xvi.
9. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001; 2: reviews3005.1-12.
10. Gospodarowicz D, Ferrara N, Neufeld G, Schweigerer L. Structural characterization and biological functions of fibroblast growth factor. Endocr Rev 1987; 8: 95-114.
11. Klagsbrun M, Edelman ER. Biological and biochemical properties of fibroblast growth factors, Implications for the pathogenesis of atherosclerosis. Arteriosclerosis 1989; 9: 269-78.
12. Burgess WH, Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 1989; 58: 575-606.
13. Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res 1992; 59:115-65.
14. Okada-Ban M, Thiery JP, Jouanneau J. Fibroblast growth factor-2. Int J Biochem Cell Biol 2000; 32: 263-7.
15. Cordon-Cardo C, Vlodavsky I, Haimovitz-Friedman A, Hicklin D, Fuks Z. Expression of basic fibroblast growth factor in normal human tissues. Lab Invest 1990; 63: 832-40.
16. Shibata F, Baird A, Florkiewicz RZ. Functional characterization of the human basic fibroblast growth factor gene promoter. Growth Factors 1991; 4: 277-87.
17. Vlodavsky I, Folkman J, Sullivan R, Fridman R, Ishai-Michaeli R, Sasse J, et al. Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci USA 1987; 84: 2292-6.
18. Mignatti P, Morimoto T, Rifkin DB. Basic fibroblast growth factor, a protein devoid of secretory signal sequence, is released by single cells via a pathway independent of the endoplasmic reticulum-Golgi complex. J Cell Physiol 1992; 151: 81-93.
19. Hou JZ, Kan MK, McKeehan K, McBride G, Adams P, McKeehan WL. Fibroblast growth factor receptors from liver vary in three structural domains. Science 1991; 251: 665-8.
20. Givol D, Yayon A. Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J 1992; 15: 3362-9.
21. Klagsbrun M The fibroblast growth factor family: structural and biological properties. Prog Growth Factor Res 1989; 1: 207-35.
22. Lindner V, Majack RA, Reidy MA. Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries. J Clin Invest 1990; 85: 2004-8.
23. Tsuboi R, Saro Y, Rifkin DB. Correlation of cell migration, cell invasion, receptor number, proteinase production, and basic fibroblast growth factor levels in endothelial cells. J Cell Biol 1990; 110: 511-7.
24. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991; 64: 841-8.
25. Ornitz DM, Yayon A, Flanagan JG, Svahn CM, Levi E, Leder P. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol 1992; 12: 240-7.
26. Arese M, Chen Y, Florkiewicz RZ, Gualandris A, Shen B, Rifkin DB. Nuclear activities of basic fibroblast growth factor: potentiation of low-serum growth mediated by natural or chimeric nuclear localization signals. Mol Biol Cell 1999; 10: 1429-44.
27. Arnaud E, Touriol C, Boutonnet C, Gensac MC, Vagner S, Prats H, et al. A new 34-kilodalton isoform of human fibroblast growth factor 2 is cap dependently synthesized by using a non-AUG start codon and behaves as a survival factor. Mol Cell Biol 1999; 19: 505-14.
28. Florkiewicz RZ, Sommer A. Human basic fibroblast growth factor gene encodes four polypeptides: three initiate translation from non-AUG codons. Proc Natl Acad Sci USA 1989; 86: 3978-81.
29. Claus P, Doring F, Gringel S, Muller-Ostermeyer F, Fuhlrott J, Kraft T, et al. Differential intranuclear localization of fibroblast growth factor-2 isoforms and specific interaction with the survival of motoneuron protein. J Biol Chem 2003; 278: 479-85.
30. Speir E, Sasse J, Shrivastav S, Casscells W. Culture-induced increase in acidic and basic fibroblast growth factor activities and their association with the nuclei of vascular endothelial and smooth muscle cells. J Cell Physiol 1991; 147: 362-73.
31. Hawker JR, Granger HJ. Internalized basic fibroblast growth factor translocates to nuclei of venular endothelial cells. Am J Physiol 1992; 262: H1525-37.
32. Hawker JR, Granger HJ. Tyrosine kinase inhibitors impair fibroblast growth factor signaling in coronary endothelial cells. Am J Physiol 1994; 266: H107-20.
33. Frautschy SA, Walicke PA, Baird A. Localization of basic fibroblast growth factor and its mRNA after CNS injury. Brain Res 1991; 553: 291-9.
34. Schweigerer L, Neufeld G, Friedman J, Abraham JA, Fiddes JC, Gospodarowicz D. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature 1987; 325: 257-9.
35. Saksela O, Moscatelli D, Rifkin DB. The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells. J Cell Biol 1987; 105: 957-63.
36. Klagsbrun M, Vlodavsky I. Biosynthesis and storage of basic fibroblast growth factor (FGF2) by endothelial cells: implication for the mechanism of action of angiogenesis. Prog Clin Biol Res 1988; 266: 55-61.
37. Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I.A heparin-binding angiogenic protein - basic fibroblast growth factor-is stored within basement membrane. Am J Pathol 1988; 130: 393-400.
38. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29(6 Suppl 16): 15-18.
39. Czubayko F, Liaudet-Coopman ED, Aigner A, Tuveson AT, Berchem GJ, Wellstein A. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med 1997; 3: 1137-40.
40. Dono R, Texido G, Dussel R, Ehmke H, Zeller R. Impaired cerebral cortex development and blood pressure regulation in FGF-2-deficient mice. EMBO J 1998; 17: 4213-25.
41. Miller DL, Ortega S, Bashayan O, Basch R, Basilico C. Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice. Mol Cell Biol 2000; 20: 2260-8.
42. Tobe T, Ortega S, Luna JD, Ozaki H, Okamoto N, Derevjanik NL, et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol 1998; 153: 1641-6.
43. Ortega S, Ittmann M, Tsang SH, Ehrlich M, Basilico C. Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. Proc Natl Acad Sci USA 1998; 95: 5672-7.
44. Zhou M, Sutliff RL, Paul RJ, Lorenz JN, Hoying JB, Haudenschild CC, et al. Fibroblast growth factor 2 control of vascular tone. Nat Med 1998; 4: 201-7.
45. Unger EF, Banai S, Shou M, Lazarous DF, Jaklitsch MT, Scheinowitz M, et al. Basic fibroblast growth factor enhances myocardial collateral flow in a canino model. Am J Physiol 1994; 266(4 Pt 2): H1588-95
46. Lazarous DF, Scheinowitz M, Shou M, Hodge E, Rajanayagam S, Hunsburger S, et al. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation 1995; 91: 145-53.
47. Horrigan MC, MacIsaac AI, Nicolini FA, Vince DG, Lee P, Ellis SG, et al. Reduction in myocardial infarct size by basic fibroblast growth factor after temporary coronary occlusion in a canine model. Circulation 1996; 94: 1927-33.
48. Rajanayagam MA, Shou M, Thirumurti V, Lazarous DF, Quyyumi AA, Goncalves L, et al. Intracoronary basic fibroblast growth factor enhances myocardial collateral perfusion in dogs. J Am Coll Cardiol 2000; 35: 519-26.
49. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000; 55: 15-35.
50. Takeshita S, Kearney M, Loushin C, Brogi E, Zheng LP, Horowitz J, et al. In vivo evidence that vascular endothelial growth factor stimulates collateral formation by inducing arterial cell proliferation in a rabbit ischemic hindlimb. J Clin Invest 1994; 93: 662-70.
51. Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N, et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995; 92(9 Suppl): 11365-71.
52. Tsurumi Y, Takeshita S, Chen D, Kearney M, Rossow ST, Passeri J, et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996; 94: 3281-90.
53. Gowdak LH, Poliakova L, Wang X, Kovesdi I, Fishbein KW, Zacheo A, et al. Adenovirus-mediated VEGF(121)gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia. Circulation 2000; 102: 565-71.
54. Gowdak LH, Poliakova L, Li Z, Grove R, Lakatta EG, Talan M. Induction of angiogenesis by cationic lipid-mediated VEGF165 gene transfer in the rabbit ischemic hindlimb model. J Vasc Surg 2000; 32: 343-52.
55. Cherng JM, Lin CM, Lin CL, Huang SM, Chang HL, Lee CC. et al. Effects of VEGF121 and/or VEGF165 gene transfection on collateral circulation development. J Formos Med Assoc 2000; 99: 603-11.
56. Kutryk MJ, Stewart DJ. Angiogenesis of the heart. Microsc Res Tech 2003; 60: 138-58.
57. Schumacher B, Pecher P, von Specht BU, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998; 97: 645-50.
58. Laham RJ, Sellke FW, Edelman ER, Pearlman JD, Ware JA, Brown DL, et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 1999; 100: 1865-71.
59. Laham RJ, Chronos NA, Pike M, Leimbach ME, Udelson JE, Pearlman JD, et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. J Am Coll Cardiol 2000: 36: 2132-9.
60. Unger EF, Goncalves L, Epstein SE, Chew EY, Trapnell CB, Cannon RO 3rd, et al. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am J Cardiol 2000; 85: 1414-9.
61. Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg 1998; 65: 1540-4.
62. Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002; 105: 788-93.
63. Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002; 105: 1291-7.
64. Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, Simons M, et al. Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease: Am Heart J 2001; 142: 872-80.
65. Hendel RC, Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation 2000; 101: 118-21.
66. Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998; 98: 2800-4.
67. Losordo DW, Vale PR, Hendel RC, Milliken CE, Fortuin FD, Cummings N, et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002; 105: 2012-8.
68. Symes JF, Losordo DW, Vale PR, Lathi KG, Esakof DD, Mayskiy M, et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 1999; 68: 830-36.
69. Vale PR, Losordo DW, Milliken CE, McDonald MC, Gravelin LM, Curry CM, et al. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 2001; 103: 2138-43.
70. Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, et al. TRAFFIC Investigators. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudicalion (the TRAFFIC study): a randomised trial. Lancet 2002; 359: 2053-8.
71. Hughes S, Yang H, Chan-Ling T. Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis, Invest Ophthalmol Vis Sci 2000; 41: 1217-28.
72. Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogonesis. Am J Physiol Cell Physiol 2002; 282: C947-70.
73. Henry PD. Hypercholesterolemia and angiogenesis. Am J Cardiol 1993; 72(suppl): 61C-4C.
74. Chen CH, Nguyen HH, Weilbaecher D, Luo S, Gotto AM Jr, Henry PD. Basic fibroblast growth factor reverses atherosclerotic impairment of human coronary angiogenesis-like responses in vitro. Atherosclerosis. 1995; 116: 261-268.
75. Chen CH, Cartwright J Jr, Li Z, Luo S, Nguyen HH, Gotto AM Jr, et al. Inhibitory effects of hypercholesterolemia and ox-LDL on angiogenesis-like endothelial growth in rabbit aortic explants. Essential role of basic fibroblast growth factor. Arterioscler Thromb Vasc Biol 1997; 17: 1303-12.
76. Chen CH, Henry PD. Atherosclerosis as a microvascular disease: impaired angiogenesis mediated by suppressed basic fibroblast growth factor expression. Proc Assoc Am Physicians 1997; 109: 351-361.
77. Bucay M, Nguy J, Barrios R, Chen CH, Henry PD. Impaired adaptive vascular growth in hypercholesterolemic rabbit. Atherosclerosis 1998; 139: 243-51.
78. Chen CH, Jiang W, Via D, Luo S, Lee TZ, Lee YT, et al. Oxidized low-density lipoproteins inhibit endothelial cell proliferation by suppressing basic fibroblast growth factor expression. Circulation 2000; 101: 171-7.
79. Chang PY, Luo S, Jiang T, Lee YT, Lu SC, Henry PD, et al. Oxidized low-density lipoprotein downregulates endothelial basic fibroblast growth factor through a pertussis toxin-sensitive G-protein pathway: mediator role of platelet-activating factor-like phospholipids. Circulation 2001; 104: 588-93.
80. Chen CH, Jiang T, Yang JH, Jiang W, Lu J, Marathe GK, et al. Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation 2003; 107: 2102-2108.
81. Metais C, Li J, Li J, Simons M. Sellke FW. Effects of coronary artery disease on expression and microvascular response to VEGF. Am J Physiol 1998; 275(4 Pt 2): H1411-8.
82. Flott-Rahmel B, Gerdes W, Peehan PA, Brysch W, Schlingensiepen KH, Seifert W. FGF2 induces its own gene expression in astrocytic and hippocampal cell cultures. Neuroreport 1992; 3: 1077-80.
83. Weich HA, Iberg N, Klagsbrun M, Folkman J. Transcriptional regulation of basic fibroblast growth factor gene expression in capillary endothelial cells. J Cell Biochem 1991; 47: 158-64.
84. Follesa P, Mocchetti I. Regulation of basic fibroblast growth factor and nerve growth factor mRNA by beta-adrenergic receptor activation and adrenal steroids in rat central nervous system. Mol Pharmacol 1993; 43: 132-8.
85. Stachowiak MK, Moffett J, Joy A, Puchacz E, Florkiewicz R, Stachowiak EK. Regulation of FGF2 gene expression and subcellular distribution of FGF2 protein in adrenal medullary cells. J Cell Biol 1994; 127: 203-23.
86. Riva MA, Fumagalli F, Racagni G. Opposite regulation of basic fibroblast growth factor and nerve growth factor gene expression in rat cortical astrocytes following dexamethasone treatment. J Neurochem 1995; 64: 2526-2553.
87. Biesiada E, Razandi M, Levin ER. Egr-1 activates basic fibroblast growth factor transcription. Mechanistic implications for astrocyte proliferation. J Biol Chem 1996; 271: 18576-81.
88. Santiago FS, Lowe HC, Day FL, Chesterman CN, Khachigian LM. Early growth response factor-1 induction by injury is triggered by release and paracrine activation by fibroblast growth factor-2. Am J Pathol 1999; 154: 937-44.
89. Silverman ES, Collins T. Pathways of Egr-1-mediated gene transcription in vascular biology. Am J Pathol 1999; 154: 665-70.
90. 1-adrenergic stimulation of fibroblast growth factor-2 promoter activity in cardiac myocytes. Mol Pharmacol 2000; 57: 984-90.
91. Cui MZ, Penn MS, Chisolm GM. Native and oxidized low density lipoprotein induction of tissue factor gene expression in smooth muscle cells is mediated by both Egr-1 and Sp1. J Biol Chem 1999; 274: 32795-802.
92. Re RN, Bryan SE. Functional intracellular rennin-angiotensin systems may exist in multiple tissues. Hypertens Clin Exp Theory Tract 1984; A6(Supple 10 and 11): 1739-42.
93. Re RN. Toward a theory of intracrine hormone action. Regul Pept 2002; 106: 1-6.
94. 1 transition. Proc Natl Acad Sci U S A 1987; 84: 6770-4.
95. Amalric F, Bouche G, Bonnet H, Brethenou P, Roman AM, Truchet I, et al. Fibroblast growth factor-2 (FGF-2) in the nucleus: translocation process and targets. Biochem Pharmacol 1994; 47:111-5.
96. Nakanishi Y, Kihara K, Mizuno K, Masamune Y, Yoshino Y, Nishikawa K. Direct effect of basic fibroblast growth factor on gene transcription in cell-free system. Proc Natl Acad Sci USA 1992; 89: 5216-20.
97. Jaakkola P, Vihinen T, Maatta A, Jalkanen M. Activation of an enhancer on the syndecan-1 gene is restricted to fibroblast growth factor family members in mesenchymal cells. Mol Cell Biol 1997; 17: 3210-9.
98. Sanderson RD, Bernfield M. Molecular polymorphism of a cell surface proteoglycan: distinct structures on simple and stratified epithelia. Proc Natl Acad Sci USA 1988; 85: 9562-6.
99. Echtermeyer F, Streit M, Wilcox-Adelman S, Saoncella S, Denhez F, Detmar M, et al. Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. J Clin Invest 2001; 107: R9-14.
100. Pursiheimo JP, Jalkanen M, Tasken K, Jaakkola P. Involvement of protein kinase A in fibroblast growth factor-2-activated transcription. Proc Natl Acad Sci USA 2000; 97: 168-73.